B-CELL MATURATION ANTIGEN (BCMA) TARGETED THERAPIES MARKET ANALYSIS
However, high cost involved in multiple combinational drug as well as maintenance therapy is expected to hinder growth of the BCMA targeted therapies market.
Increasing number of recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market
The patients undergoing chemotherapy and radiation therapy are at high risk of recurrence of cancer as they develop resistance to these therapy. At present there are no treatment options for patients with recurrent cancer and hence the BCMA targeted therapies provide breakthrough therapeutic options for the treatment of relapsed or refractory multiple myeloma, where the existing treatment modalities have proved to be clinically inefficient.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowPress Release
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :